Showing results (441-450 of 587) with videos related to

Sort By:
Pageof 59
JAMA Network Open|November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical TrialsPasi A Jänne, David Planchard, Koichi Goto, et al.
European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.
The Lancet. Oncology|September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMICJose Carlos Benitez, Marie-Ève Boucher, Eric Dansin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2018
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseFrançois-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
The Lancet. Oncology|September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trialJordi Remon, Paolo Bironzo, Nicolas Girard, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 26, 2023
Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancerJérôme Cartry, Sabrina Bedja, Alice Boilève, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Pageof 59